The following board members, constituting a quorum, were present:
Elaine Albert, Frederick Appelbaum, Thomas Brown (phone), David Byrd, Carol Dahl (phone),
Eunice Hostetter (phone), Jennifer Kampsula Wong (phone)

Board Members Absent: Leslie Alexandre, Weihang Chai, Steven Harr, James Hendricks

Guest Attendees: Thomas Bates, Sarah Lyman, Peter Choi

The CARE Board met on Wednesday, December 13, 2017 at 3:00 p.m. at Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA.

3:07 p.m.  Welcome and Roll Call (Fred Appelbaum)

3:10–3:13 p.m.  Consent Agenda (Fred Appelbaum)
The Consent Agenda Items were presented:
- October 25, 2017 CARE Board Meeting Minutes
- CARE Match and Allowable Costs policy
- Distinguished Researcher Grant Award Agreement

There was clarification of the Match Policy allowing the use of federal funds only attributable to the proposed research as match. The federal costs for standard patient care is not allowed as a match. It was proposed that the language on publicizing the CARE award should be strengthened. It was proposed that CARE staff be permitted to modify the Award Agreement as necessary to execute the grant awards. Substantive modifications would have to be reviewed by Sandra Adix, CARE’s Assistant Attorney General.

Motion was made, seconded, and it was unanimously resolved to approve the Consent Agenda Items with the noted changes.

3:13 – 4:23 p.m.  CARE Distinguished Researcher AAAS Review and Funding Decision (Fred Appelbaum)
Ground rules for discussing Distinguished Researcher Application reviews were discussed. Potential Conflicts of Interest were disclosed. Consensus that the American Association for the Advancement of Science (AAAS) reviews of the applications were clear, thorough, balanced, and responsive to CARE Board priorities.

There was discussion of available CARE Fund balance and whether to limit the number of Distinguished Researcher Awards for the first cohort.
The six applications that received a “Highly Recommended” or a “Recommended” rating were discussed, in accordance with conflicts of interest policy. All six Distinguished Researcher applicants were approved to receive an award (see details about the voting process below). One award was approved contingent on appropriate documentation of an item raised in the AAAS Review. Board member(s) with a potential conflict of interest recused themselves from the voting as detailed below.

<table>
<thead>
<tr>
<th>Distinguished Researcher</th>
<th>Vote</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Heath</td>
<td>Unanimously approved; (Abstained from vote: Tom Brown)</td>
</tr>
<tr>
<td>Sam Lee</td>
<td>Unanimously approved, with contingency for appropriate documentation of AAAS issue; (Abstained from vote: David Byrd, Fred Appelbaum; Elaine Albert)</td>
</tr>
<tr>
<td>Heather Greenlee</td>
<td>Unanimously approved; (Abstained from vote: David Byrd, Fred Appelbaum)</td>
</tr>
<tr>
<td>Mark Headley</td>
<td>Unanimously approved; (Abstained from vote: Fred Appelbaum)</td>
</tr>
<tr>
<td>Jeffrey Henderson</td>
<td>Unanimously approved</td>
</tr>
<tr>
<td>Lev Silberstein</td>
<td>Unanimously approved; (Abstained from vote: Fred Appelbaum)</td>
</tr>
</tbody>
</table>

There was general agreement that CARE would reopen the next round of Distinguished Researchers call for proposals in early 2018 (aiming for February 1). The cycle will remain open for applications until after the CARE Board has a chance to do an initial review of the LOIs received in the Breakthrough Research call for proposals (mid April). This will give the board some sense of potential funding levels available for the next cohort of DR grants, depending on the quality of Breakthrough LOIs received.

4:23 – 4:59 p.m. Breakthrough Research Program (Fred Appelbaum)

There was a discussion on the revised Breakthrough Research Program Description. There was discussion about the time between the deadlines in the application process. There was consensus to extend the Letter of Interest time period to 8 weeks and extend the full proposal time period to 12 weeks. There was discussion to strengthen the language to allow for more robust review process from phase 1 (year 1) funding to phase 2 funding.

Motion was made, and seconded, and unanimously resolved to make changes to the Breakthrough Program Description as discussed, and authorize the subcommittee to make a final approval.

4:59 p.m. Meeting Adjourned

Dated: 1/18/2019

Eunice Hostetter
CARE Board Secretary